Skip to main content
Beyfortus® logo

Addressing Parental Concerns


Practical guidance and conversation tools to help you address parental hesitancy around infant immunization against RSV lower respiratory tract disease and build confidence in your ongoing and seasonal communication about Beyfortus® (nirsevimab-alip).

Communication tips

Research has shown that effective communication can improve immunization acceptance from parents.1,2
Sanofi is committed to ensuring that immunization information is presented in a manner that parents will be receptive to while also helping to build parental confidence.

The number 1

Start with a presumptive approach

Begin conversations with intention rather than asking for vaccination preferences. Studies suggest this approach is associated with higher uptake of childhood vaccines.3

Try saying:

“Today, we’re going to immunize your baby with Beyfortus to protect against serious RSV disease.”

  

The number 2

Give a personal recommendation

Parents trust their pediatricians and nurses. A personal endorsement carries significant weight in their decision-making.3

Try saying:

“I recommend Beyfortus for all babies in my practice, and as a parent, I would give it to my own baby.”

  

The number 3

Keep the door open

Not all parents will immediately agree. It’s important to understand their concerns and revisit the conversation at future visits.3

Try saying:

“If you’re not ready today, that’s okay—we’ll talk about it again at the next appointment.”

  

Building trust with the AIMS method

An evidence-based approach for more effective conversations with parents and caregivers.4

ANNOUNCE

Announce that immunization is recommended and approach the conversation with confidence rather than asking for immunization preferences. 

   
Example: “RSV season is nearing. Let’s talk about how to help protect your baby.”

INQUIRE

Inquire and seek to understand the parent by asking them about their concern(s) or hesitation around immunization. 

   
Example: “Do you have any questions for me?”

MIRROR

Mirror their perspective or concern(s).

  • Restate to demonstrate that you understand their point of view without validating the particular concern(s); you can express understanding and support

   
Example: “You have some safety concerns about immunization, if I’m understanding correctly?”

SECURE

Secure their trust, regardless of their decisions about immunizations.

  • It’s important to maintain a good relationship to facilitate future conversations, not only with you but also with other providers

   
Example: “It’s great to see a parent ensuring their baby’s safety. Let’s break this down and talk through it.”

Key messages

Research shows parents are looking for reassurance in these key areas:

Established

“More than 11 million babies worldwide have received Beyfortus.”5*
This social proof point establishes that parents and pediatricians around the world have chosen Beyfortus for their babies.

Effective

“One dose protects for 5 months—throughout a typical RSV season.”6,7†
This helps overcome resistance to “another shot” by emphasizing the duration of protection.

Tested

“Preventive antibodies like Beyfortus have been tested and trusted to help protect babies for over 25 years.”8,9 
Mentioning this history reassures parents who are concerned about “newness.”

Recommended

“The AAP recommends an RSV preventive antibody, such as Beyfortus, for all eligible infants during the RSV season.”10,11‡§
Guideline recommendations communicate expert consensus and carry authority.

*Supported by global estimated exposure based on calculation from sales volume data (September 1, 2023, through October 31, 2025). The number of children exposed is estimated based on the distribution of the recommended dose of Beyfortus administered, considering body weight, season of administration (1st or 2nd), and immunization plan.5
†Based on clinical data.
‡Recommended for eligible infants <8 months old between October 1 and March 31. Timing of administration for RSV immunization may differ in certain areas.10,11
§Beyfortus is not needed for most infants aged <8 months whose mother received the RSV maternal vaccine ≥14 days before birth.11

Common concerns

Here are the most common concerns parents express, along with suggested responses based on evidence and clinical guidelines.

Understanding serious RSV disease—protection starts with you

Discover more about Beyfortus

Want to know more about Beyfortus?

Explore downloadable resources

Demonstrated safety and efficacy profile

AAP, American Academy of Pediatrics; AIMS, Announce, Inquire, Mirror, Secure; FAQs, frequently asked questions; FDA, US Food and Drug Administration; IM, intramuscular; RSV, respiratory syncytial virus.

Important Safety Information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important Safety Information

Indication

References: 1. Brewer NT, Hall ME, Malo TL, et al. Announcements versus conversations to improve HPV vaccination coverage: a randomized trial. Pediatrics. 2017;139(1):e20161764. 2. Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics. 2013;132(6):1037-1046. 3. Talking with parents about vaccines. Centers for Disease Control and Prevention. Updated August 9, 2024. Accessed July 28, 2026. https://www.cdc.gov/vaccines-children/hcp/conversation-tips/index.html 4. Parrish-Sprowl J, Thomson A, Johnson RD, et al. The AIMS approach: regulating receptivity in patient-provider vaccine conversations. Front Public Health. 2023;11:1120326. 5. Data on File. Sanofi. 6. Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi. 7. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018;217(9):1356-1364. 8. Liu JKH. The history of monoclonal antibody development—progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116. 9. Esposito S, Abu Raya B, Baraldi E, et al. RSV prevention in all infants: which is the most preferable strategy? Front Immunol. 2022;13:880368. 10. Immunizations to protect infants. Centers for Disease Control and Prevention. Updated August 18, 2025. Accessed July 28, 2026. https://www.cdc.gov/rsv/vaccines/protect-infants.html 11. Recommended child and adolescent immunization schedule for ages 18 years or younger. American Academy of Pediatrics. Updated February 5, 2026. Accessed July 14, 2026. https://downloads.aap.org/AAP/PDF/AAP-Immunization-Schedule.pdf 12. About RSV. Centers for Disease Control and Prevention. Updated December 30, 2025. Accessed July 17, 2026. https://www.cdc.gov/rsv/causes/index.html 13. How RSV spreads. Centers for Disease Control and Prevention. Updated February 20, 2026. Accessed July 14, 2026. https://www.cdc.gov/rsv/causes/index.html 14. Cacho F, Gebretsadik T, Anderson LJ, et al. Respiratory syncytial virus prevalence and risk factors among healthy term infants, United States. Emerg Infect Dis. 2024;30(10):2199-2202. 15. RSV in infants and young children. Centers for Disease Control and Prevention. Updated February 20, 2026. Accessed July 13, 2026. https://www.cdc.gov/rsv/infants-young-children/index.html 16. Suh M, Movva N, Jiang X, et al. Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample. J Infect Dis. 2022;226(suppl 2):S154-S163. 17. Preliminary estimates of RSV burden. Centers for Disease Control and Prevention. Updated February 6, 2026. Accessed July 23, 2026. https://www.cdc.gov/rsv/php/surveillance/burden-estimates.html 18. Gantenberg JR, van Aalst R, Zimmerman N, et al. Medically attended illness due to respiratory syncytial virus infection among infants born in the United States between 2016 and 2020. J Infect Dis. 2022;226(suppl 2):S164-S174. 19. Arriola CS, Kim L, Langley G, et al. Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged <2 years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9(5):587-595. 20. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341-e348. 
21. Bianchini S, Silvestri E, Argentiero A, et al. Role of respiratory syncytial virus in pediatric pneumonia. Microorganisms. 2020;8(12):2048. 22. Rainisch G, Adhikari B, Meltzer MI, et al. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine. 2020;38(2)(suppl):251-257. 23. Demont C, Petrica N, Bardoulat I, et al. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis. 2021;21(1):730. 24. Gantenberg JR, Thompson KD, van Aalst R, et al. Inpatient service utilization amongst infants diagnosed with respiratory syncytial virus infection (RSV) in the United States. PLoS One. 2025;20(1):e0317367. 25. Heikkinen T, Valkonen H, Waris M, et al. Transmission of respiratory syncytial virus infection within families. Open Forum Infect Dis. 2015;2(1):ofu118. 26. Lambert L, Sagfors AM, Openshaw PJ, et al. Immunity to RSV in early-life. Front Immunol. 2014;5:466. 27. Pickles RJ, DeVincenzo JP. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis. J Pathol. 2015;235(2):266-276. 28. Explaining how vaccines work. Centers for Disease Control and Prevention. Updated August 10, 2024. Accessed July 14, 2026. https://www.cdc.gov/vaccines/basics/explaining-how-vaccines-work.html 29. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415-425. 30. Hammitt LL, Dagan R, Yuan Y, et al; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-846. 31. Ullah I, Khan KS, Tahir MJ, et al. Myths and conspiracy theories on vaccines and COVID-19: potential effect on global vaccine refusals. Vacunas. 2021;22:93-97. 32. Immunization information statement. Respiratory syncytial virus (RSV) preventive antibody: what you need to know. Centers for Disease Control and Prevention. Updated September 25, 2023. Accessed July 14, 2026. https://www.cdc.gov/vaccines/hcp/current-vis/downloads/Immunization-Information-Statement.pdf

MAT-US-2310577-v9.0-08/2026